Dicerna Announces Appointment of Ralf Rosskamp, M.D., as Chief Medical Officer
June 08 2017 - 7:30AM
Business Wire
Dicerna Pharmaceuticals, Inc. (Nasdaq: DRNA), a leading
developer of investigational ribonucleic acid interference (RNAi)
therapeutics, today announced the appointment of industry veteran
Ralf Rosskamp, M.D., as chief medical officer, effective June 15,
2017. Dr. Rosskamp brings to Dicerna more than 20 years of research
and development (R&D) experience spanning the entire drug
development cycle, from pre-clinical through product
commercialization. He will be responsible for leading the Company’s
clinical development, medical affairs and regulatory functions.
“Dr. Rosskamp is an accomplished biopharmaceutical executive
with extensive global drug development and product launch
experience across numerous therapeutic areas, including large
population diseases such as cardiovascular disease, and, more
recently, rare and orphan diseases,” said Douglas M. Fambrough,
Ph.D., president and chief executive officer of Dicerna. “His
in-depth experience, combined with his proven success in working
with global regulatory agencies to obtain multiple drug approvals,
including most recently the FDA approval of Natpara® for the
treatment of a rare endocrine disorder called hypoparathyroidism,
will be a huge asset to Dicerna. Dr. Rosskamp will play an integral
role as we seek to advance our lead product, DCR-PHXC, into the
clinic in early 2018, and continue to advance our broad pipeline of
other promising GalXC™-based drug candidates.”
Dr. Rosskamp joins Dicerna from Summit Therapeutics where he
served as chief medical officer. In this capacity, he was
responsible for directing and overseeing all clinical development
and medical activities for Summit’s clinical candidates in
development for the rare genetic disease Duchenne muscular
dystrophy and the infectious disease caused by Clostridium
difficile bacteria. Prior to Summit, Dr. Rosskamp held
executive-level positions in clinical research and drug development
at NPS Pharmaceuticals (acquired by Shire), Ikaria, Kos
Pharmaceuticals (acquired by Abbott Laboratories), Aventis
Pharmaceuticals (formerly Hoechst Marrion Roussel), and Hoechst AG.
Dr. Rosskamp has been responsible for numerous investigational new
drug applications, the design and execution of clinical development
programs, and new drug applications across multiple therapeutic
areas including diabetes, cardiovascular, respiratory, and orphan
drugs. In addition to Natpara®, approved products for which Dr.
Rosskamp was involved include Amaryl®, Lantus®, Apidra® and
Simcor®.
Dr. Rosskamp is a member of the Board of Directors of Bioblast
Pharma in Tel Aviv, Israel. He has authored more than 20
peer-reviewed publications and published more than 50 scientific
abstracts. Dr. Rosskamp is a pediatric endocrinologist with more
than 15 years of experience in clinical medicine. He received his
M.D. from the University of Bonn, Germany.
“I am delighted to join Dicerna at this pivotal time, and to
have the opportunity to lead the clinical development of the
Company’s pipeline of novel RNAi compounds,” said Dr. Rosskamp.
“Dicerna has developed a differentiated technology platform that
has generated a strong and growing pipeline of pre-clinical
candidates capable of silencing genes in the liver across a
spectrum of diseases, opening up a range of therapeutic
opportunities for the Company. I look forward to working closely
with the Dicerna team to initiate clinical studies early next year
for its lead program, DCR-PHXC, which is being developed for
patients with primary hyperoxaluria type 1, a devastating and rare
genetic disease with limited treatment options.”
About Dicerna Pharmaceuticals, Inc.
Dicerna Pharmaceuticals, Inc. is a biopharmaceutical company
focused on the discovery and development of innovative ribonucleic
acid interference (RNAi)-based therapeutics for diseases involving
the liver, including rare diseases, chronic liver diseases,
cardiovascular diseases, and viral infectious diseases. The Company
is leveraging its proprietary GalXC™ RNAi technology platform to
build a broad pipeline in these core therapeutic areas, focusing on
target genes where connections between target gene and diseases are
well understood and documented. The Company intends to discover,
develop, and commercialize novel therapeutics either on its own or
in collaboration with pharmaceutical partners. For more
information, please visit www.dicerna.com.
Cautionary Note on Forward-Looking Statements
This press release includes forward-looking statements,
including, for example, our anticipated timeline and plans for
development. Such forward-looking statements are subject to risks
and uncertainties that could cause actual results to differ
materially from those expressed or implied in such statements.
Applicable risks and uncertainties include risks relating to our
preclinical and clinical research and other risks identified under
the heading "Risk Factors" included in our most recent Form 10-K
filing and in other future filings with the SEC. The
forward-looking statements contained in this press release reflect
Dicerna's current views with respect to future events, and Dicerna
does not undertake and specifically disclaims any obligation to
update any forward-looking statements.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20170608005211/en/
Investors:Rx Communications Group, LLCPaula Schwartz,
917-322-2216pschwartz@rxir.comorMedia:SmithSolveAlex Van
Rees, 973-442-1555 ext. 111alex.vanrees@smithsolve.com
Dicerna Pharmaceuticals (NASDAQ:DRNA)
Historical Stock Chart
From Mar 2024 to Apr 2024
Dicerna Pharmaceuticals (NASDAQ:DRNA)
Historical Stock Chart
From Apr 2023 to Apr 2024